Milestones

The following is a list of milestone documents, compiled by the National HPV Vaccination Roundtable, which chronicles notable events in U.S.-based HPV vaccine history, from 2006 to present.

2020

Launch of the global strategy to accelerate the elimination of cervical cancer

On November 17, 2020, following the close of the 73rd World Health Assembly, WHO officially launched the cervical cancer global elimination strategy. Due to the pandemic. the event was held virtually and hosted by WHO leadership. The governments of Australia, Botswana, Lesotho, Malawi, Nigeria, and Rwanda co-sponsored the event.

2020

FDA Approves Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers

2019

ACIP updates recommendation to harmonize HPV vaccination and to add shared clinical decision making for adults 27-45

2018

President's Cancer Panel issues a report: HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to Action

2018

National HPV Vaccination Roundtable established by the American Cancer Society and the Centers for Disease Control and Prevention

2014

FDA licenses quadrivalent HPV vaccine (HPV4/Gardasil) for use in males aged 9 through 26 years for prevention of genital warts on October 16, 2009

2009

FDA licenses bivalent HPV vaccine (HPV2/Cervarix) for females on October 16, 2009

2007

Advisory Committee on Immunization Practices (ACIP) issues recommendations on quadrivalent HPV vaccine

2006

Milestones

Milestones

Launch of the global strategy to accelerate the elimination of cervical cancer

FDA Approves Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers

ACIP updates recommendation to harmonize HPV vaccination and to add shared clinical decision making for adults 27-45

President's Cancer Panel issues a report: HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to Action

FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old

Cancer Moonshot Blue Ribbon Panel Report highlights cancer prevention potential of HPV vaccination

ACIP updates recommendations on use of a 2-dose schedule for HPV vaccination

NCI-designated Cancer Centers issue consensus statement on HPV vaccination

ACIP issues updated recommendations on use of 9-valent HPV vaccine

FDA approves nine valent vaccination (9vHPV/Gardasil 9)

National HPV Vaccination Roundtable established by the American Cancer Society and the Centers for Disease Control and Prevention

ACIP issues new recommendations for HPV vaccination

President’s Cancer Panel issues 2012-2013 Report: Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer

ACIP issues guidance on quadrivalent vaccine (HPV4/Gardasil) for use in males

ACIP issues updated HPV vaccination recommendations for HPV2 and HPV4 for females

FDA licenses quadrivalent HPV vaccine (HPV4/Gardasil) for use in males aged 9 through 26 years for prevention of genital warts on October 16, 2009

FDA licenses bivalent HPV vaccine (HPV2/Cervarix) for females on October 16, 2009

Advisory Committee on Immunization Practices (ACIP) issues recommendations on quadrivalent HPV vaccine

U.S. Food and Drug Administration (FDA) approves quadrivalent (HPV4/Gardasil) human papillomavirus vaccine for females on June 8, 2006

Milestones

Milestones

Launch of the global strategy to accelerate the elimination of cervical cancer

FDA Approves Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers

ACIP updates recommendation to harmonize HPV vaccination and to add shared clinical decision making for adults 27-45

President's Cancer Panel issues a report: HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to Action

FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old

Cancer Moonshot Blue Ribbon Panel Report highlights cancer prevention potential of HPV vaccination

ACIP updates recommendations on use of a 2-dose schedule for HPV vaccination

NCI-designated Cancer Centers issue consensus statement on HPV vaccination

ACIP issues updated recommendations on use of 9-valent HPV vaccine

FDA approves nine valent vaccination (9vHPV/Gardasil 9)

National HPV Vaccination Roundtable established by the American Cancer Society and the Centers for Disease Control and Prevention

ACIP issues new recommendations for HPV vaccination

President’s Cancer Panel issues 2012-2013 Report: Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer

ACIP issues guidance on quadrivalent vaccine (HPV4/Gardasil) for use in males

ACIP issues updated HPV vaccination recommendations for HPV2 and HPV4 for females

FDA licenses quadrivalent HPV vaccine (HPV4/Gardasil) for use in males aged 9 through 26 years for prevention of genital warts on October 16, 2009

FDA licenses bivalent HPV vaccine (HPV2/Cervarix) for females on October 16, 2009

Advisory Committee on Immunization Practices (ACIP) issues recommendations on quadrivalent HPV vaccine

U.S. Food and Drug Administration (FDA) approves quadrivalent (HPV4/Gardasil) human papillomavirus vaccine for females on June 8, 2006

Twitter Feed